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Summary
 
NK recognition is regulated by a delicate balance between positive signals initiating their effec-
tor functions, and inhibitory signals preventing them from proceeding to cytolysis. Knowledge
of the molecules responsible for positive signaling in NK cells is currently limited. We demon-
strate that IL-2–activated human NK cells can express CD40 ligand (CD40L) and that recogni-
tion of CD40 on target cells can provide an activation pathway for such human NK cells.
CD40-transfected P815 cells were killed by NK cell lines expressing CD40L, clones and PBL-
derived NK cells cultured for 18 h in the presence of IL-2, but not by CD40L-negative fresh
NK cells. Cross-linking of CD40L on IL-2–activated NK cells induced redirected cytolysis of
CD40-negative but Fc receptor-expressing P815 cells. The sensitivity of human TAP-deficient
T2 cells could be blocked by anti-CD40 antibodies as well as by reconstitution of TAP/MHC
class I expression, indicating that the CD40-dependent pathway for NK activation can be
downregulated, at least in part, by MHC class I molecules on the target cells. NK cell recogni-
tion of CD40 may be important in immunoregulation as well as in immune responses against B
cell malignancies.
 
N
 
K cells represent a distinct lineage of lymphocytes that
are able to kill a variety of tumor (1), virus-infected (2),
bone marrow transplanted (3), and allogeneic target cells
(4). NK cells do not express T cell receptors or immuno-
globulins and are apparently normal in mice with defects in
the recombinase machinery (5, 6).
Our knowledge about NK cell specificity has increased
considerably in the last years. NK cells can probably inter-
act with target cells by a variety of different cell surface
molecules, some involved in cell adhesion, some activating
the NK cytolytic program (7, 8), and other ones able to in-
hibit this activation by negative signaling (as reviewed in
reference 9).
A common feature of several inhibitory NK receptors is
the capability to bind MHC class I molecules (10, 11), as
predicted by the effector inhibition model within the miss-
ing self hypothesis of recognition by NK cells (12–14).
Interestingly, the MHC class I receptors identified so far
belong to different gene families in mouse and man; these
are  the p58/p70/NKAT or killer cell inhibitory receptors
(KIR)
 
1
 
 of the immunoglobulin superfamily in man and the
Ly49 receptors of the C-type lectin family in the mouse.
There is also evidence that MHC class I molecules can be
recognized as triggering signals in NK cells of humans, rats
as well as mice (13). The inhibitory receptors allow NK
cells to kill tumor or normal cell targets with deficient
MHC class I expression (12, 14). This does not exclude
that other activating pathways can override inhibition by
MHC class I molecules (15) and, even in their absence,
there must be some activating target molecules that initiate
the cytolytic program. Several surface molecules are able to
mediate positive signals in NK cells. Some of these struc-
tures, like NKRP1 (16), CD69 (17), and NKG2 (18) map
to the NK complex region (NKC) of chromosome 6 in
mice and of chromosome 12 in humans (13). CD2 (19) and
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Abbreviations used in this paper:
 
 CD40L, CD40 ligand; KIR, killer cell in-
hibitory receptors; o.n., overnight.
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CD16 (20) molecules can also play a role in the activation
pathway.
NK cells resemble T cells in many respects, both may
arise from an immediate common progenitor (21, 22), and
share the expression of several surface molecules (23). NK
cells produce cytokines resembling those secreted by some
helper T cell subsets (24) and contain CD3 components in
the cytoplasm (21). The expression of some surface struc-
tures, involved in TCR-dependent T cell costimulation,
like CD28 in human (25), has been described on NK cells,
but the functional relevance of these molecules for NK ac-
tivation processes has not been fully established.
Another T cell molecule of interest is CD40L, which in-
teracts with CD40, a 50-kD membrane glycoprotein ex-
pressed on B cells (26), dendritic cells (27), and monocytes
(28). CD40 is a member of the tumor necrosis factor/nerve
growth factor receptor family (29) which includes CD27
(30), CD30 (31), and FAS antigen (32). Murine and human
forms of CD40L had been cloned and found to be mem-
brane glycoproteins with a molecular mass of 
 
 
 
39 kD in-
duced on T cells after activation (33). Also mast cells (34),
eosinophils (35), and B cells (36) can be induced to express
a functional CD40L. The CD40L–CD40 interaction has
been demonstrated to be necessary for T cell–dependent B
cell activation (33, 37). Mutations in the CD40L molecule
cause a hyper-IgM immunodeficiency condition in man
(38, 39, 40). On the other hand, CD40–CD40L interac-
tions also orchestrate the response of regulatory T cells dur-
ing both their development (41, 42) and their encounter
with antigen (43, 44).
NK cells have also been suggested to play a role in B cell
differentiation and immunoglobulin production (45). There-
fore, it was of interest to investigate whether NK cells could
use a CD40-dependent pathway in their interactions with
other cells. Therefore, we have investigated the ability of
target cells expressing CD40 to induce activation of NK
cytotoxicity.
 
Materials and Methods
 
Cell Lines.
 
K562, an MHC class I–negative human erythro-
leukemia cell line, T2 and T2/TAP1
 
 
 
2, transfectants of the T2
T-B lymphoblast hybrid line (46), were cultured in RPMI 1640
(Biochrom K.G., Berlin, Germany) supplemented with 5% heat-
inactivated FCS and 2 mM glutamine (Biochrom) at 37
 
 
 
C in 5%
CO
 
2
 
/95% air. In the T2/TAP1
 
 
 
2 culture the medium was sup-
plemented weekly with 600 
 
 
 
g/ml G-418 (Sigma Chemical Co.,
St. Louis, MO). Murine mastocytoma P815 cells stably trans-
fected with human CD40 cDNA containing plasmid expression
vectors (43, 47), were a generous gift of Dr. L. Lanier (DNAX,
Palo Alto, CA). These cell lines are referred to as CD40-P815
throughout.
 
Monoclonal Antibodies, Immunofluorescence, and Flow Cytome-
try.
 
mAb W6/32, (an IgG2a anti-HLA mAb recognizing a class
I monomorphic determinant) was purchased from DAKO (Mi-
lan, Italy); mAb OKT3 (IgG2a anti-CD3) and TIB-200 (IgM anti-
CD57) were obtained from hybridomas provided by the Ameri-
can Type Culture Collection (Rockville, MD); mAb 14G7 (IgM
anti-CD40) was a gift of Dr. R. van Lear (Central Laboratory of
the Blood Transfusion Service, Amsterdam, The Netherlands);
TRAP-1 (IgG1 anti-CD40L) was purchased from PharMigen (San
Diego, CA); OX27 (IgG1, anti-rat MHC class I) was purchased
from Serotec (Oxford, England). FITC- and PE-labeled mAbs
against CD3, CD4, CD8, CD14, CD19, CD56, CD2, CD16,
and isotype-matched labeled controls were purchased from Bec-
ton Dickinson (Mountain View, CA) and used to characterize the
cell phenotype by immunofluorescence. Immunofluorescence, flow
cytometry and data analysis were performed as described (48). To
detect the CD40L expression on polyclonal IL-2–activated lym-
phocytes, PBMC, depleted of adherent cells, were incubated for
the indicated periods in round-bottomed 96-well microtiter plates
(Falcon; Becton Dickinson). At the indicated times, cells were
washed in PBS and incubated for 30 min at 4
 
 
 
C with saturating
concentrations of PE-labeled TRAP-1 mAb in the presence of
FITC-labeled anti-CD3 or anti-CD56 or isotypic controls in a
standard double-staining technique.
 
NK Polyclonal Populations, NK Lines, and NK Clones.
 
PBMC were isolated by centrifugation on Ficoll Hypaque (Bio-
chrom) gradients from normal donor buffy coats obtained from
the Blood Bank of the Medical School of the Federico II Univer-
sity of Naples. After isolation, the PBMC were washed and incu-
bated in complete medium, in a horizontally placed plastic flask,
for 2 h at 37
 
 
 
C to remove adherent cells. The recovered cells
were used without any pretreatment or activated with 
 
r
 
IL-2 as in-
dicated in the results section. In some experiments, IL-2–acti-
vated effectors were depleted of CD3-positive cells by magnetic
beads (Dynal, Oslo, Norway) coated with anti-CD3 mAb and a
samarium cobalt magnet. The depletion procedure was repeated
twice. 98% of the remaining cells were CD56
 
 
 
CD3
 
 
 
, as assessed
by FACS
 

 
 analysis. CD56
 
 
 
CD3
 
 
 
 effector populations were gen-
erated using anti-CD56 mAb-coated beads and the same deple-
tion procedure. The NK3.3 human NK cell line was obtained from
a healthy donor as described (49) and cultured in the presence of
1,000 IU/ml of human recombinant IL-2 (
 
r
 
IL-2). The JA2 NK
clone was generated and characterized as described (50).
 
Cytotoxicity Assay.
 
Cytotoxicity was measured in a conven-
tional 4-h 
 
51
 
Cr-release assay. Target cells were labeled with
Na
 
2
 
51CrO
 
4 
 
(100 
 
 
 
Ci/2 
 
 
 
 10
 
6
 
 cells) and the percent of specific
lysis was calculated as ([experimental release
 
   
 
spontaneous re-
lease] / [maximum release
 
   
 
spontaneous release]) 
 
 
 
 100. The
spontaneous release never exceeded 20%. Experimental details
and mAb concentrations used in the reverse ADCC test as well as
in the treatment of NK effectors with plastic immobilized anti-
bodies are indicated in Results.
 
Results
 
A CD40-dependent Activation Pathway Is Involved in Cyto-
toxicity Mediated by NK Clones and IL-2–activated NK
Cells.
 
In an effort to assess the role of costimulatory mol-
ecules in NK activation, we studied the ability of the NK
line NK3.3 and clone JA2 to recognize and kill P815 mas-
tocytoma cells and their CD40 transfectants. Fig. 1 shows
that the transfection of CD40 molecule is able, alone, to
induce recognition and lysis of P815 targets by NK3.3 ef-
fectors (Fig. 1 
 
A
 
). Similar results were obtained with the
NK clone JA2 (Fig. 1 
 
B
 
). Five NK clones were tested using
the same target systems, giving comparable results (data not
shown). Any interference due to possible clonal differences
in the target susceptibility could be excluded by blocking 
2055
 
Carbone et al.
 
experiments in which a chromium release assay was per-
formed in the presence of targets pretreated with anti-CD40
IgM mAb 14G7 or with the isotypic control TIB-200 mAb
(Fig. 1, 
 
C
 
). These data indicated that a CD40-dependent
pathway is functionally involved in the induction of cyto-
toxicity of human NK cell lines and clones. In contrast,
fresh polyclonal NK cells that had not been exposed to IL-2
were not able to recognize the CD40-transfected targets
(Fig. 2 
 
A
 
). However, PBMC depleted of plastic-adherent
cells and activated with 
 
r
 
IL-2 (1,000 IU/ml) were able to
recognize and kill CD40 transfectants. P815 parental cells
were not killed. The effect was detectable after 18 h of cul-
ture with IL-2, reached its maximum after 48 h and was
still evident after 72 h of IL-2 treatment (Fig. 2 
 
C
 
). Deple-
tion by magnetic beads of CD56
 
 
 
 but not CD3
 
 
 
 lympho-
cytes completely inhibited the killing of CD40-transfected
P815 (Figs. 3, 
 
A
 
 and 
 
B
 
). We conclude that a CD40-depen-
dent cytotoxic pathway is functional, not only in human
NK lines and clones, but also in polyclonal 
 
r
 
IL-2–activated
NK effectors, isolated from peripheral blood of normal in-
dividuals.
 
Expression of CD40L by NK Clones and IL-2–activated
CD3
 
 
 
CD56
 
 
 
 Lymphocytes.
 
To better characterize the in-
duction of the CD40-dependent cytotoxic pathway in the
human NK lines and clones, we studied their expression of
surface CD40L. Fig. 4 shows profiles obtained by staining
the NK3.3 cell line (
 
A
 
) and JA2 NK clone (
 
B
 
) with the
anti-CD40L mAb TRAP-1. Both NK populations ex-
Figure 1. CD40 molecules are
able to activate NK-dependent
killing. P815 (open circles) and
CD40-P815 (closed circles) cells
were used as targets in a classical
chromium release assay. A and B
indicate % lysis obtained with
NK cell line NK3.3 and NK
clone JA2, respectively. C shows
a representative experiment in
which NK3.3 NK cell line was
tested in a classical chromium re-
lease assay in the presence of
CD40-transfected P815 target
preincubated with medium
(closed circles), with the IgM anti-
CD40 mAb 14G7 (open squares),
or with the control anti-CD57
mAb TIB-200 (open triangles).
Both mAb were used as 1:1,000
ascites dilution.
Figure 2. Effect of IL-2 incu-
bation on the cytotoxic activity
of NK polyclonal effectors
against CD40 expressing targets,
and time titration curves. A and
B indicate % lysis obtained by us-
ing freshly isolated or o.n. IL-2–
activated polyclonal NK cells,
respectively, in the presence of
CD40-P815 (closed circles), P815
parental cells (open circles). Data
obtained from 18 independent
donors were analyzed by two-
tailed paired Student’s t test; the
killing differences between P815
and CD40-P815 were found sta-
tistically significant (P   0.002).
C indicates results obtained by
using polyclonal NK effectors
incubated with rIL-2 for the in-
dicated time in the presence of
CD40-P815 (closed circles) or
P815 (open circles); E/T ratio was
always 50:1. Results refer to one
of five independent experiments. 
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pressed CD40L molecule. We also assessed the expression
of CD40L on polyclonal NK effectors derived from pe-
ripheral blood of normal donors, by double staining with
anti-CD40L mAb TRAP-1 and anti-CD3 or anti-CD56
mAb. A clear TRAP-1 binding on the CD3
 
 
 
CD56
 
 
 
 pop-
ulation was demonstrated after overnight (o.n.) incubation
in the presence of 
 
r
 
IL-2, but not with medium alone (Fig.
5). No binding was observed on fresh cells (data not shown).
These data indicate that CD3
 
 
 
CD56
 
 
 
 NK effectors, acti-
vated with 
 
r
 
IL-2, can express the CD40L molecule; this is
likely to account for their ability to specifically recognize
and kill CD40-expressing targets.
 
Killing of Resistant Targets Induced by Cross-linking of CD40L
on Human Cell Lines.
 
We investigated next whether cross-
linking of CD40L can induce signals able to activate NK
killing. We took advantage of the observation that the
P815 parental line is completely resistant to lysis by the
NK3.3 cell line (Fig. 1 
 
A
 
), and in addition expresses Fc re-
ceptors. It should thus be possible to induce CD40L
 
 
 
NK3.3 cells to lyse the Fc receptor-expressing P815 by cross-
linking CD40L with TRAP-1 in a reverse ADCC experi-
ment. Fig. 6 shows one of five independent experiments in
which such an effect was demonstrated. Pretreatment of
P815 cells with TRAP-1 mAb, but not with the isotypic
control OX27 recognizing the rat MHC class I antigens,
was able to induce killing by NK3.3 effectors. Target treat-
ment with 200 ng of anti-CD40L mAb TRAP-1 or the
isotypic control OX27 was performed as previously de-
scribed (51). We observed a similar phenomenon using two
other IL-2–activated NK cell lines (data not shown). NK3.3
cells starved from IL-2 could not be activated by CD40L
cross-linking (Fig. 6 
 
B
 
), although they efficiently kill K562
NK-susceptible control cell line (data not shown). These
data indicate that CD40L triggering induces a cytotoxic
pathway in the 4-h period required for a standard 
 
51
 
Cr-release
assay. In an effort to better investigate the role of CD40L
engagement in the induction of a cytotoxic phenotype in
human NK effectors, we performed experiments in which
NK cells were incubated for 4 h at 37
 
 
 
C with plastic-immobi-
lized  anti-CD40L mAb TRAP-1 or the isotypic control
OX27 and then used in a classical chromium release assay
Figure 3. CD40-transfected P815 are killed by IL-2–activated NK
cells. (A) Percent lysis obtained by using CD3-depleted, IL-2–activated
effectors, prepared as described in Materials and Methods, in the presence
of CD40-P815 (closed circles), or P815 parental cells (open circles). (B) CD3-
depleted (closed symbols) or CD56-depleted (open symbols) effectors, ob-
tained by two unrelated donors, were tested for their ability to lyse
CD40-P815 transfectants in a classical chromium release assay. Results re-
fer to one of three independent experiments.
Figure 4. CD40 Ligand expression on NK3.3 cell line and JA2 NK
clone. Staining profiles obtained by using anti-CD40L TRAP-1 mAb or
isotypic controls, as indicated. A and B show the NK3.3 NK cell line and
JA2 NK clone staining data, respectively.
Figure 5. CD56 CD3  lymphocytes express CD40L after incubation
with IL-2. Staining profiles of o.n. cultured lymphocytes, obtained as
indicated in the Materials and Methods section, by using PE-labeled anti-
CD40L TRAP-1, FITC-labeled anti-CD3, or anti-CD56 mAbs in a clas-
sical double fluorescence assay. Results were evaluated as histograms
referring to TRAP-1 binding on CD3  or CD56  gated cell. The com-
parison with the binding obtained in the counterpart population (CD3 /
CD56 ) was performed by histogram overlapping, as indicated. The anal-
ysis was performed on the same population of lymphocytes cultured o.n.
in the presence of medium (A and C) or with rIL-2 (B and D), respec-
tively.2057 Carbone et al.
in the presence of the CD40-negative resistant target P815.
Fig. 6 C shows the results obtained in a representative ex-
periment. As shown, preincubation of NK3.3 cell line ef-
fectors for 4 h in the presence of coated TRAP-1 mAb, but
not the isotypic control OX27 enables NK cells to signifi-
cantly kill P815 targets. Therefore, CD40L engagement
clearly induces human NK effectors to recognize and kill
CD40-negative resistant targets.
Regulation of CD40-dependent NK Cytotoxicity by Target
Cell Class I Expression. NK cell recognition is regulated
by a delicate balance between positive signals, that initiate
their effector function, and inhibitory signals that prevent
cytolysis. Negative signals can be mediated by MHC class I
molecules. Therefore, we tested the ability of NK3.3 NK
effectors to kill the T2 cell line, in which a defect in TAP1–
TAP2 peptide transporter genes leads to reduced MHC
class I surface expression. TAP1 2 transfectants of T2 (T2/
TAP1 2), in which the defect was completely reconsti-
tuted, were used as controls. These cell lines constitutively
express similar levels of the CD40 costimulatory molecules,
as assessed by indirect immunofluorescence (data not shown).
Fig. 7 shows one representative experiment, in which the
pretreatment of T2 cells with anti-CD40, but not with
anti-CD57 mAb, significantly inhibited NK3.3-dependent
cytotoxicity. If we used T2/TAP1 2 cells as targets in the
same experimental model, the cytotoxic effect was com-
pletely inhibited (Fig. 7). The activating signals, mediated
by costimulatory molecules, may therefore be modulated
by the presence of optimal levels of surface HLA class I an-
tigens. However, data obtained by using a panel of more
potent NK effectors revealed a residual susceptibility to NK
lysis of target cells expressing MHC class I and CD40.
Therefore, we cannot exclude that the triggering effect of
CD40 can override MHC class I–dependent negative sig-
nals (data not shown) under other conditions.
Discussion
There is an emerging consensus that NK cell recognition
is regulated by a balance between positive signals, which
initiate their effector functions, and inhibitory signals pre-
venting cytolysis. At present, there is no evidence for a
unique NK cell–specific receptor, responsible for positive
signaling in NK cells; rather, it is likely that different recep-
tors may be used, depending on the activation state of the
NK cell and the availability of the relevant ligands on the
target cell.
Figure 6. CD40 ligand cross-
linking induces redirected cyto-
toxicity. P815 cells were incubated
with 200 ng of anti-CD40L
mAb TRAP-1 (closed circles), the
isotypic control OX27 (open tri-
angles), or medium (open circles)
and then used as target in an in
vitro cytotoxicity assay. The re-
sults refer to one of five indepen-
dent experiments. A and B show
data obtained by using as effec-
tors NK3.3 cells cultured in the
presence of rIL-2 or starved from
IL-2 for 24 h, respectively. C
shows data obtained by using
NK3.3 effectors pre-incubated
for 4 h at 37 C in the presence of
plastic immobilized TRAP-1
mAb, or the control OX27
mAb. The treatment was per-
formed in a 96-well microtiter
plate precoated with 50  l of the antibody solution, at the concentration of 10  g/ml. NK effectors were collected and used in a classical chromium re-
lease assay. Closed and open circles indicate preincubation of effectors in the presence of plastic immobilized TRAP-1 or OX27 control mAb, respec-
tively. The results refer to one of four independent experiments.
Figure 7. The reexpression of MHC class I on NK targets expressing
CD40 is able to inhibit NK3.3-mediated cytotoxicity. Percent lysis ob-
tained by using effector NK3.3 cell line in the presence of untreated T2
cells (open circles), T2 preincubated with the anti-CD57 IgM mAb TIB-
200 (open triangles), with the anti-CD40 IgM mAb 14G7 (closed triangles).
Closed circles indicate cytotoxicity obtained with T2/TAP1 2 targets.
The results refer to one representative experiment out of four performed.2058 CD40L-CD40 Interaction Mediates NK Cytotoxicity Activation
This study demonstrates that a CD40-mediated activa-
tion pathway is functional in the induction of cytotoxicity
mediated by IL-2–activated NK cells in humans. This ef-
fect is likely to be mediated by surface-expressed CD40L
on human IL-2–activated CD3 CD56  lymphocytes. To
the best of our knowledge, this receptor has not been de-
scribed earlier on NK cells. We found that fresh NK cells
from normal donors did not express CD40L and were un-
able to kill the CD40 transfectants. Activation with IL-2
induced the CD40L as well as the capability to kill CD40
expressing targets. CD40L is normally expressed by T cells
6–8 h after activation, then it is quickly downmodulated
(52). It is possible that a CD40-dependent pathway is func-
tional also in NK effectors in vivo after activation with rel-
evant stimuli. Our findings thus add the CD40–CD40L in-
teraction to other triggering pathways for NK cells.
Previous reports (45, 53) demonstrated that NK cells can
induce B cell maturation as well as immunoglobulin secre-
tion and isotype switching. Our data open the possibility
that these phenomena might in part be mediated by a
CD40–CD40L interaction. CD40L  T cells were recently
described to induce IL-12 secretion by human peripheral
blood monocytes, favoring Th1 priming in vitro (54, 55).
mAb directed against CD40L molecules were able to pre-
vent Th1-mediated IFN-  secretion in the same experi-
mental model. Therefore, one may speculate as to whether
NK cells expressing CD40L can mediate immunoregulatory
functions. Our results suggest that negative signals mediated
by MHC class I molecules on target cells can downregulate
NK killing also when CD40 costimulatory molecules are
involved in the triggering of cytotoxicity. These data sug-
gest the possibility that the NK effector encounter with an
APC could play a role in the regulation of some immune
responses. The final outcome of this interaction could de-
pend on the balance between activating molecules, like co-
stimulatory structures, and MHC class I antigens expressed
on the surface of the APC. In this context, inhibitory re-
ceptors, recognizing self MHC class I molecules and ex-
pressed on NK effectors, may serve as a fail-safe mechanism
to prevent inappropriate responses and destruction of nor-
mal cells expressing CD40. Under some circumstances, sol-
uble mediators, like inflammatory cytokines, may alter the
balance between MHC class I inhibitory signals and co-
stimulatory positive stimuli, activating the NK effector func-
tion. This could imply elimination of infected cells or old
APCs no longer needed and potentially harmful by giving a
persistent stimulation of a response.
NK cells can express distinct receptor sets able to control
NK cytotoxicity. Inhibitory receptors were described to rec-
ognize MHC class I antigens expressed on targets cell sur-
face, however some isoforms of such kind of receptors were
also able to trigger NK cytotoxicity (13). Here we propose
CD40L as a new NK activating molecule. Our observa-
tions suggest that the functional pathways involved in the
induction of NK cytotoxicity rather than redundant, might
be able to complement each other. In this context, the
presence on the surface of NK effectors of activating recep-
tors for MHC class I molecules, could be involved in the
induction of cytotoxic mechanisms during allogeneic bone
marrow rejection, or be able to sense modification in the
structure or peptide loading of self MHC class I molecules
expressed on the surface of infected cells. At variance, a role
for CD40L in mechanisms of NK-mediated immune regu-
lation, likely involving CD40 expressing targets, as mono-
cytes and dendritic cells, could also be proposed. In addi-
tion, high CD40 expression levels might override MHC
class I–mediated inhibition of NK cytotoxicity.
Recent observations, obtained in CD40–CD40L knock-
out murine models, have demonstrated a critical role for
CD40–CD40L interaction in the activation of T cells in
vivo (44, 56). Two possible mechanisms are believed to
likely account for such a role. First, CD40L might be a re-
ceptor for T cell costimulation by CD40 expressing APC
(42, 43); second, CD40L may be an inducer of costimula-
tory activity and the induced costimulatory molecules are
essential for T cell activation (57, 58). Our data indicate
that CD40L triggering enables human NK effectors to rec-
ognize and kill resistant targets. On the other hand, we are
not able to discriminate if CD40L engagement on NK cells
can directly affect the cytotoxicity machinery or mediates
the induction of distinct molecules in order to activate the
NK lysis programs. Similar findings were already referred
to in CD40 knockout mice, in which in vivo priming in
the presence of soluble CD40 was shown to partially over-
come the need for CD40 expressing B cells in order to ob-
tain a mature antibody response and to generate memory
cell populations (56).
The described CD40–CD40L NK activation pathway is
disrupted in the hyper-IgM immunodeficiency syndrome.
These patients have a defective CD40L expression, leading
to an impairment of the Ig switch and persistency of IgM
production. Many of the infections in these patients can be
attributed to the resulting lack of the humoral response.
Some are more typical of defective cell-mediated response.
The results presented here suggest that these pathologies
might be due to a defective CD40L expression on NK cells.
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